In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MDxHealth SA

www.mdxhealth.com

Latest From MDxHealth SA

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.

Market Intelligence Cancer

MDx Health Signs Exclusive Canadian Agreement

MDx Health has signed an exclusive distribution deal to make its liquid biopsy prostate cancer test available in Canada.

Canada Cancer

Pacts In Medtech: May/June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in May and June 2017.

Commercial Deals

MDxHealth Prostate Cancer Test Identifies Increased Risk of Cancer Recurrence

MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).

Cancer In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Therapeutic Drug Monitoring
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • OncoGenome Sciences
  • OncoMethylome Sciences SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • MDxHealth SA
  • Senior Management
  • Michael K McGarrity, CEO
    Jean-Marc Roelandt, CFO
    Joseph Sollee, EVP, Corp. Dev. & Gen. Counsel
    Michael K Brawer, MD, CMO
  • Contact Info
  • MDxHealth SA
    Phone: (32) 4 364 20 70
    CAP Business Center
    Rue d’Abhooz,31
    Herstal, B-4040
    Belgium
UsernamePublicRestriction

Register